GB2414668A — Sustained release delivery system for tetracycline compounds
Assigned to Dexcel Ltd Israel · Expires 2005-12-07 · 20y expired
What this patent protects
An encapsulated two tablet dosage system comprising at least one quick release tablet and at least one delayed release tablet is disclosed, wherein each tablet has a diameter of greater than 3mm. A method of preparing such a two tablet delivery system is also provided. Also discl…
USPTO Abstract
An encapsulated two tablet dosage system comprising at least one quick release tablet and at least one delayed release tablet is disclosed, wherein each tablet has a diameter of greater than 3mm. A method of preparing such a two tablet delivery system is also provided. Also disclosed is a method for preparation of a pharmaceutical delivery system, by forming quick release cores with a diameter greater than 3mm, coating with an enteric coating to form a delayed release tablet and optionally coating to form quick release tablets. Also provided is an encapsulated pharmaceutical system comprising two tablets adapted to provide a therapeutically effective blood concentration level of minocycline.
Drugs covered by this patent
- Tygacil (TIGECYCLINE) · Fresenius Kabi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.